Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Research Report - Global Forecast till 2030

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Information By Treatment (Intravenous Immunoglobulin, Corticosteroids, Plasmapheresis (Plasma Exchange), Physiotherapy, Others), Diagnosis (Electrodiagnostic Testing, Nerve Conduction, EMG, Spinal Fluid Analysis, Others), By Route of Administration (Intravenous, Oral, Others), By End User (Hospitals, Specialty Neurological Clinics, Research & Academic Laboratories, Others) and Top Regions Forecast till 2030.

ID: MRFR/HC/5482-CR | December 2018 | Region: Global | 124 pages         

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market at a CAGR of 7.50% to hit $ 2723.42 Million by 2030

Segmentation

By Treatment Intravenous Immunoglobulin Corticosteroids Plasmapheresis (Plasma Exchange) Physiotherapy
By Diagnosis Electrodiagnostic Testing Nerve Conduction EMG Spinal Fluid Analysis
By Route of Administration Intravenous Oral
By End User Hospitals Specialty Neurological Clinics Research & Academic Laboratories

Key Players

  • Bio Products Laboratory Ltd.
  • Momenta Pharmaceuticals
  • Grifols
  • Baxter
  • Kedrion S.p.A
  • Octapharma
  • Shire
  • Mitsubishi Tanabe Pharma Corporation
  • CSL Behring
  • Teijin Pharma Limited

Drivers

  • Surging awareness about the disease and government endeavors
Speak to Analyst Request a Free Sample

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market


Market overview


According to the latest research report, the chronic inflammatory demyelinating polyneuropathy market size is poised to increase at a compound annual growth rate of a CAGR of 7.50 percent during the forecast timeframe of 2020-2030 reaching USD 6,577.10 million by the end of the review period. In 2017, the global market for chronic inflammatory demyelinating polyneuropathy was valued at USD 2723.42 million. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a serious neurological autoimmune condition in which the immune system attacks myelin, an important component of the nervous system. It is a medical disorder in which the body naturally cannot distinguish between its tissues and other cells, resulting in the maintenance of healthy body cells being attacked. 


In recent years, there's been an exponential increase in the frequency of autoimmune illnesses, which bodes well for the future development of the worldwide chronic inflammatory demyelinating polyneuropathy disease market. Patients who suffer from autoimmune illnesses are more prone to get the disease than other patients. The increasing number of cases of CIDP has sparked widespread worry in the medical community, particularly in affluent nations. The CIDP area has benefited from the efforts of a number of governmental and commercial entities that have conducted research and development operations that have achieved beneficial results. Through intensive research and development efforts as well as clinical studies, some remarkable outcomes were obtained. The FDA has approved many new medications, and they have been introduced into the industry, which is helping to develop the chronic inflammatory demyelinating polyneuropathy market value as a whole. Other factors contributing to the market's expansion include increased awareness of the illness and government initiatives to combat the condition.


This report contains all the information on the global chronic inflammatory demyelinating polyneuropathy market analysis and its strengths. The report also contains the culmination of dynamics, segmentation, key players, regional analysis, and other essential factors. And a detailed analysis of the chronic inflammatory demyelinating polyneuropathy market forecast for 2027 is also included in the report.


 Covid 19 Analysis


In response to the epidemic of coronavirus illness in 2019 (COVID-19), substantial segments of the medical industry have turned to telemedicine in order to make patient visits more convenient. Based on a video visit during the COVID-19 outbreak, we present a case of a 50-year-old woman who was subsequently confirmed as having CIDP and managed with intravenous immunoglobulins, with improvement in clinical examination and electrodiagnostic tests. As seen in this scenario, telemedicine cannot be used to conduct neuromuscular assessment due to technical restrictions.


Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Dynamic                  


Drivers


Rising increasing understanding of CIPD increased research & innovation affiliated with plasma-derived medications, increased government assistance via awareness programs and drug authorizations, and increased incidence of this illness coupled with increased government involvement to support patients with chronic inflammatory conditions demyelinating polyneuropathy are among the key factors driving the demand. In addition, healthcare expenditure rules and nonprofit organization engagement will generate new chances for the chronic inflammatory demyelinating polyneuropathy (CIDP) market growth.


Opportunities


Meanwhile, the high unmet demand for innovative alternative treatments for the condition is expected to bring new possibilities to the forefront for market participants over the course of the projection year.


Restraints


On the negative side, the rising price of intravenous immunoglobulin therapy and the adverse effects associated with its injection, such as hypotension, nausea, back muscles discomfort, flushing, chills, wheezing, and other symptoms, continue to be a hurdle to the market's expansion.


Challenges


However, side effects associated with Intravenous Immunoglobulin (IVIG) treatment, an increase in the cost of treating CIPD, and the accessibility of restricted alternative treatments are among the key causes acting as constraints. These will continue to pose a threat to the chronic inflammatory demyelinating polyneuropathy (CIDP) market throughout the forecast period mentioned above and in the following years.


Cumulative Growth Analysis


The frequency of autoimmune illnesses seems to be rising. Autoimmune illnesses affected almost 50 million Americans in 2017, according to the American Autoimmune Related Diseases Association. A hereditary predisposition to chronic inflammatory demyelinating polyneuropathy has not been discovered and can affect anybody, irrespective of genetic composition. An upsurge in therapy research & innovation has come from this. Research and development in plasma-derived therapies are likely to drive expansion in the chronic inflammatory demyelinating polyneuropathy market value


Privigen, a novel intravenous immune globulin therapy for CIDP, was approved by the FDA in 2017 as a consequence. Since chronic inflammatory demyelinating polyneuropathy (CIDP) is becoming more well known, the market is being bolstered (CIDP). Demand will be bolstered by an increase in the number of cases of chronic inflammatory demyelinating polyneuropathy and state assistance for those affected. Many reasons contribute to the market's rapid expansion, including favorable reimbursement regulations and the engagement of nonprofit groups.


Value Chain Analysis


According to the reports, the global chronic inflammatory demyelinating polyneuropathy market has been segmented into By Treatment & Diagnosis, Route of Administration, End User, and regions. According to the treatment method, the chronic inflammatory demyelinating polyneuropathy (CIDP) market is divided into intravenous immunoglobulin, corticosteroids, physiotherapy, plasmapheresis, and other types of treatment. The chronic inflammatory demyelinating polyneuropathy (CIDP) market is split into spinal fluid analysis, electrodiagnostic testing, electromyography, nerve conduction testing, and others based on the method of diagnosis.


The chronic inflammatory demyelinating polyneuropathy (CIDP) market is classified into three categories based on the method of administration: intravenous, oral, and others. According to end-user, the chronic inflammatory demyelinating polyneuropathy (CIDP) market is divided into hospitals, specialist neurology clinics and research & academic labs, amongst others.


Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Segmentation Overview


The market is segmented By Treatment & Diagnosis, Route of Administration, End User, and regions. The global chronic inflammatory demyelinating polyneuropathy market trend is expected to witness decent growth during the forecast period.


By Application


The Application is segmented into spinal fluid analysis, electrodiagnostic testing, electromyography, nerve conduction testing, and others.


By end-users


The market is segmented into hospitals, specialist neurology clinics and research & academic labs, amongst others.


Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Regional Analysis


According to the reports, on the basis of region global chronic inflammatory demyelinating polyneuropathy market is divided into the Americas, Europe, Asia Pacific, and the middle east and Africa. As a result of the increase in research & innovation related to plasma-derived therapies and the increase in government assistance via awareness campaigns and drug licenses, Asia-Pacific has dominated the chronic inflammatory demyelinating polyneuropathy (CIDP) industry. The chronic inflammatory demyelinating polyneuropathy (CIDP) market share in the Asia Pacific is expected to expand at a fast pace over the forecast timeframe, due mainly to the country's rapid urbanization and the resulting rapidly deteriorating of levels of air pollution, both of which are expected to contribute to a rise in the prevalence of autoimmune conditions.


 Competitive landscape


There are several companies in the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, all of whom are competing for your attention. Certain global market leaders have amassed a sizable portion of the total market by capitalizing on their good position and visibility in a large number of nations and locations across the globe.


Major Key Players



  • Bio Products Laboratory Ltd.

  • Momenta Pharmaceuticals

  • Grifols

  • Baxter

  • Kedrion S.p.A

  • Octapharma

  • Shire

  • Mitsubishi Tanabe Pharma Corporation

  • CSL Behring

  • Teijin Pharma Limited

  • Pfizer, Inc.


Report Overview


The following report comprises of –



  • Market overview 

  • Covid 19 Analysis

  • Market Dynamic

  • Drivers

  • Opportunities

  • Restraints 

  • Challenges

  • Cumulative Growth Analysis

  • Value Chain Analysis

  • Segmentation Overview 

  • By Application 

  • By End-Users

  • Regional Analysis

  • Competitive landscape


Recent Developments



  • After the FDA granted clearance for ADMA biologics, Inc.'s BIVIGAM product offering in May 2019, the company stated that it will commence retail production of the drug in June 2019.

  • According to the Food and Drug Administration, a new intravenous immunoglobulin developed by ADMA biologics, Inc. and intended for use in the treatment of primary immunodeficiency, known as Asceniv (Immune Globulin Intravenous, Human - slra 10 percent, liquid), was approved in April 2019.


Segmental Analysis By Treatment & Diagnosis



  • TreatmentIntravenous Immunoglobulin

  • Corticosteroids

  • Plasmapheresis (plasma exchange)

  • Physiotherapy

  • Others

  • Diagnosis

  • Electrodiagnostic Testing

  • Nerve Conduction

  • EMG

  • Spinal Fluid Analysis

  • Others


Chronic Inflammatory Demyelinating Polyneuropathy Market By Route of Administration



  • Intravenous

  • Oral

  • Others


Chronic Inflammatory Demyelinating Polyneuropathy Market By End User



  • Hospitals

  • Specialty Neurological Clinics

  • Research & Academic Laboratories

  • Others


Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, by Region



  • Americas



  • US

  • Canada




    • North America

    • Latin America


  • Europe



  • Germany

  • France

  • Italy

  • Spain

  • UK

  • Rest of Western Europe




    • Western Europe

    • Eastern Europe


  • Asia-Pacific


    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Rest of Asia-Pacific


  • The Middle East & Africa


    • Middle East

    • Africa



Frequently Asked Questions



  1. Who has the most powerful position in the market?


Answer - Shire has established a substantial presence in the market for rare illnesses. Because of the purchase of Baxalta by the Baxter group, the firm is expected to post double-digit annual price top-line growth throughout the projection timeframe, according to the analysts. Shire is now operating 50 clinical research initiatives in 100 countries, which will assist the corporation in generating the greatest amount of money possible in the foreseeable future. In 2017, the corporation had a share of the market of 20.5 percent of the overall market.


Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a rare neurological autoimmune disorder where myelin, an essential part of the nervous system is being attacked by the body's immune system. It is a medical condition where the body's immune system fails to differentiate between own cells and foreign cells and starts attacking its healthy cells. As per the analysis of Market Research Future (MRFR), the chronic inflammatory demyelinating polyneuropathy market is aiming for a CAGR of 6.2% and is due to reach USD 3907.17 Mn by the end of the forecast period of 2018-2023. The chronic inflammatory demyelinating polyneuropathy market stood at USD 2723.42 Mn in 2017.


There has been a spiraling rise in the prevalence of autoimmune disorders in the recent past which offers scope for the growth of the global chronic inflammatory demyelinating polyneuropathy disease market. Patients suffering from autoimmune disorders are more likely to suffer from the disease. Growing incidences of CIDP has evoked major concern within the medical sector, especially in the developed countries. Various public, as well as private organizations, have undertaken initiatives for R&D activities which has yielded positive outcomes in the CIDP space. Noteworthy results have been achieved through rigorous R&D efforts and clinical trials. Various new drugs have been launched into the market after recent FDA approvals which also boosts the growth of the chronic inflammatory demyelinating polyneuropathy market. Other factors encouraging the growth of the market include surging awareness about the disease and government endeavors regarding the same.


the downside, the high cost of Intravenous immunoglobulin treatment and the side effects accompanied with its administration such as hypotension, nausea, lower back pain, flushing, chills, wheezing, etc. remain hindrance to the growth of the market. Meanwhile, high unmet need for advanced treatment options for the disease is likely to bring to view new opportunities for market players over the forecast period.


Chronic Inflammatory Demyelinating Polyneuropathy Market Players Covered


Bio Products Laboratory Ltd., Momenta Pharmaceuticals, Grifols, Baxter, Kedrion S.p.A, Octapharma, Shire, Mitsubishi Tanabe Pharma Corporation, CSL Behring,Teijin Pharma Limited, Pfizer, Inc. are the key players in the chronic inflammatory demyelinating polyneuropathy market. 

Segmental Analysis By Treatment & Diagnosis



  • TreatmentIntravenous Immunoglobulin

  • Corticosteroids

  • Plasmapheresis (plasma exchange)

  • Physiotherapy

  • Others

  • Diagnosis

  • Electrodiagnostic Testing

  • Nerve Conduction

  • EMG

  • Spinal Fluid Analysis

  • Others


Chronic Inflammatory Demyelinating Polyneuropathy Market By Route of Administration



  • Intravenous

  • Oral

  • Others


Chronic Inflammatory Demyelinating Polyneuropathy Market By End User



  • Hospitals

  • Specialty Neurological Clinics

  • Research & Academic Laboratories

  • Others


Chronic Inflammatory Demyelinating Polyneuropathy Market Report Overview


This MRFR report provides a forward-looking perspective on the different factors influencing the growth of the Chronic inflammatory demyelinating polyneuropathy market. Drivers, restraints, opportunities, challenges and other factors are discussed in detail to promote a deeper understanding of the market dynamics. The report covers a detailed profile of key players, their market share, geographical presence, strategies adopted by them and changing competition dynamics. Various treatment methods such as intravenous immunoglobulin, corticosteroids, plasmapheresis, physiotherapy, and others are covered.  The diverse end user segments included in the report are hospitals, specialty neurological clinics, research & academic laboratories, and others.  The report analyzes the key competencies of key players and provides insights into the strategies adopted by them to gain an edge over the market. Geographical presence of each player, their market share, country-level analysis and revenue forecast for each segment has also been provided in the report.


Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, by Region



  • Americas



  • US

  • Canada




    • North America

    • Latin America


  • Europe



  • Germany

  • France

  • Italy

  • Spain

  • UK

  • Rest of Western Europe




    • Western Europe

    • Eastern Europe


  • Asia-Pacific


    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Rest of Asia-Pacific


  • The Middle East & Africa


    • Middle East

    • Africa



Research Methodology


MRFR provides thoroughly studied market reports by combining the right mix of primary and secondary research methods, to aid clients to achieve their business goals. MRFR's research modules are designed with a specialized approach to meet industry-specific standards. A skilled team of analyst employs primary research techniques such as questionnaires, interviews, and personal interaction with key level market participants to collect valuable information about the market. Data collected from secondary sources such as white papers, annual reports, company websites, paid databases are combined with primary data to provide high-quality, accurate, and unbiased results.



Report Scope:
Report Attribute/Metric Details
  Market Size   USD 3907.17 Million
  CAGR   7.50% (2020-2030)
  Base Year   2020
  Forecast Period   2020-2030
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   By Treatment, Diagnosis, By Route of Administration, End User
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Bio Products Laboratory Ltd., Momenta Pharmaceuticals, Grifols, Baxter, Kedrion S.p.A, Octapharma, Shire, Mitsubishi Tanabe Pharma Corporation, CSL Behring,Teijin Pharma Limited, Pfizer, Inc.
  Key Market Opportunities   Joint ventures, strategic alliances, mergers and acquisitions and new product developments
  Key Market Drivers   Surging awareness about the disease and government endeavors


Speak to Analyst Ask for Customization

Frequently Asked Questions (FAQ) :

Shire has established a substantial presence in the market for rare illnesses. Because of the purchase of Baxalta by the Baxter group, the firm is expected to post double-digit annual price top-line growth throughout the projection timeframe, according to the analysts. Shire is now operating 50 clinical research initiatives in 100 countries, which will assist the corporation in generating the greatest amount of money possible in the foreseeable future. In 2017, the corporation had a share of the market of 20.5 percent of the overall market.

Numerous players are operating in the Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market. Some of the big players have captured a significant share in the global market, taking advantage of their strong position and presence in the number of countries and regions across the world.


The top players in the global chronic inflammatory demyelinating polyneuropathy (CIDP) market are Grifols, CSL Behring, Shire, Octapharma, and Kedrion S.p.A. Grifols held the first position in the global chronic inflammatory demyelinating polyneuropathy (CIDP) market with a 25.9% market share in 2017. It is one of the largest and fastest growing market players in the plasma-derived medicines market. The company has a strong presence in the Americas and Europe, but when it comes to Asia-Pacific and the Middle Eastern and African region, its presence is negligible. Grifols had been showing a constant growth in revenues from the last three years. In terms of profitability, the bioscience segment is contributing the maximum.


CSL Behring accounted for the second-largest market share of 23.4% in 2017. CSL has a strong presence in the global market, and its financial condition is stable as compared to other market players. The net profit of the company was USD 1,337 million during 2016 to2017 and USD 1,729 million from 2017 to 2018. The company paid a dividend of USD 1.2 per share for 2017 to 2018. CSL is investing huge money in R&D, and the approval of the Food and Drug Administration (FDA) for Hizentra for the treatment of CIDP can provide favorable conditions for the company to strengthen its position in the global chronic inflammatory demyelinating polyneuropathy (CIDP) market.


Shire holds a strong position in the rare diseases market. The company is likely to show a double-digit compound annual top-line growth during the forecast period owing to the acquisition of Baxalta from Baxter group. The revenue of shire increased from USD 6,416.7 million to USD 11,397 million after the acquisition Baxalta. Shire is running 50 clinical development programs in 100 countries which will help the company to generate maximum revenue in the future. The company accounted for 20.5% of the total market share in 2017.


Octapharma holds the fourth largest position in the global chronic inflammatory demyelinating polyneuropathy (CIDP) market with a market share of 8.5%. It has a strong distribution network of plasma collection centers in more than 95 countries. Ongoing research and development activities and product approvals are going to help Octapharma to increase its market share in the global chronic inflammatory demyelinating polyneuropathy (CIDP) market.


Kedrion S.p.A is into research and development of treatment for rare diseases. The company offers services related to contract research and manufacturing. The company also outsources manufacturing services from other market players. Currently, the company is outsourcing manufacturing services from Grifols Therapeutics Inc for Gammaked. It holds the fifth largest position in the global chronic inflammatory demyelinating polyneuropathy (CIDP) market with a market share of 2.4%.